Published in J Gen Virol on March 01, 2005
Occult persistence and lymphotropism of hepatitis C virus infection. World J Gastroenterol (2008) 1.01
Soluble egg antigen of Schistosoma Haematobium induces HCV replication in PBMC from patients with chronic HCV infection. BMC Infect Dis (2006) 0.93
Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J Virol (2012) 0.91
Differential expression of candidate virus receptors in human T lymphocytes prone or resistant to infection with patient-derived hepatitis C virus. PLoS One (2013) 0.83
Direct effects of hepatitis C virus on the lymphoid cells. World J Gastroenterol (2013) 0.82
Biological significance of HCV in various kinds of lymphoid cells. Int J Microbiol (2012) 0.81
Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy. PLoS One (2013) 0.81
Effects of HCV on basal and tat-induced HIV LTR activation. PLoS One (2013) 0.81
Hepatitis C virus upregulates B-cell receptor signaling: a novel mechanism for HCV-associated B-cell lymphoproliferative disorders. Oncogene (2015) 0.79
Persistence of hepatitis C virus in peripheral blood mononuclear cells of sustained viral responders to pegylated interferon and ribavirin therapy. Dig Dis Sci (2008) 0.78
The altered expression of α1 and β3 subunits of the gamma-aminobutyric acid A receptor is related to the hepatitis C virus infection. Eur J Clin Microbiol Infect Dis (2011) 0.77
Occult hepatitis C virus infection and its relevance in clinical practice. J Clin Exp Hepatol (2012) 0.77
A New Twist to a Chronic HCV Infection: Occult Hepatitis C. Gastroenterol Res Pract (2015) 0.77
Persistence of Hepatitis C Virus Traces after Spontaneous Resolution of Hepatitis C. PLoS One (2015) 0.76
Patient-derived hepatitis C virus inhibits CD4⁺ but not CD8⁺ T lymphocyte proliferation in primary T cells. Virol J (2015) 0.75
Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response. Korean J Hepatol (2011) 0.75
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol (2004) 2.27
Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response. Radiology (2006) 1.95
Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol (2011) 1.79
A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med (2006) 1.67
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Hepatitis C: a review for primary care physicians. CMAJ (2006) 1.60
Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol (2010) 1.60
Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents. Can J Gastroenterol (2002) 1.50
Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology (2002) 1.50
The diversity of O-linked glycans expressed during Drosophila melanogaster development reflects stage- and tissue-specific requirements for cell signaling. J Biol Chem (2008) 1.47
Hepatic portal venous gas: a report of two cases and a review of the epidemiology, pathogenesis, diagnosis and approach to management. Can J Gastroenterol (2007) 1.46
Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology (2003) 1.42
Journals' impact and pecking order: tyranny and tyrannosaurs. Liver Int (2012) 1.39
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol (2010) 1.38
Brain-specific rescue of Clock reveals system-driven transcriptional rhythms in peripheral tissue. PLoS Genet (2012) 1.27
Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology (2007) 1.27
The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol (2007) 1.25
Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver. J Virol (2004) 1.23
Cirrhotic cardiomyopathy. Semin Liver Dis (2008) 1.21
Therapy insight: Cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol (2006) 1.19
Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol (2010) 1.18
Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int (2008) 1.13
Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study. Liver Int (2007) 1.11
Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol (2005) 1.10
Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterol (2007) 1.09
Nocardia cyriacigeorgica septicemia. J Clin Microbiol (2006) 1.07
miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci U S A (2013) 1.06
Hydrogen sulphide synthesis in the rat and mouse gastrointestinal tract. Dig Liver Dis (2009) 1.06
Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol (2006) 1.06
Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol (2011) 1.05
Cirrhotic cardiomyopathy. Orphanet J Rare Dis (2007) 1.03
Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology (2009) 1.03
Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol (2007) 1.02
How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int (2013) 1.01
Prediction of cardiac complications after liver transplantation. Transplantation (2009) 1.00
Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol (2005) 0.99
De novo infection and propagation of wild-type Hepatitis C virus in human T lymphocytes in vitro. J Gen Virol (2006) 0.98
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int (2005) 0.98
Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus. J Virol (2008) 0.98
Amiodarone hepatotoxicity. Curr Vasc Pharmacol (2008) 0.98
The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver. Eur J Immunol (2002) 0.97
Occult hepatitis C virus infection: what does it mean? Liver Int (2010) 0.97
Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol (2009) 0.97
Management of hepatitis C virus genotype 4. J Gastroenterol Hepatol (2004) 0.97
Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection. BMC Gastroenterol (2013) 0.97
Flow cytometric quantification of T cell proliferation and division kinetics in woodchuck model of hepatitis B. Immunol Invest (2005) 0.97
Persistence of isolated antibodies to woodchuck hepatitis virus core antigen is indicative of occult infection. Hepatology (2004) 0.96
Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity. J Virol (2006) 0.96
Cirrhotic cardiomyopathy. Gastroenterol Clin Biol (2002) 0.95
Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin Sci (Lond) (2002) 0.93
Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl (2011) 0.92
Emergency management of bleeding esophageal varices: drugs, bands or sleep? Can J Gastroenterol (2006) 0.92
Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J Virol (2012) 0.91
Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression. Hepatology (2002) 0.90
Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment. J Med Virol (2012) 0.89
Portal vein thrombosis: should anticoagulation be used? Curr Gastroenterol Rep (2013) 0.89
Quantitative detection of hepadnavirus-infected lymphoid cells by in situ PCR combined with flow cytometry: implications for the study of occult virus persistence. J Virol (2003) 0.89
Cirrhotic cardiomyopathy. Ann Hepatol (2006) 0.88
Profound suppression of chronic hepatitis C following superinfection with hepatitis B virus. Liver Int (2007) 0.88
Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity. Cancer Discov (2013) 0.87
Nuclear factor-kappaB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. Liver Int (2008) 0.85
Venous thromboembolism in cirrhosis: a review of the literature. Can J Gastroenterol (2012) 0.85
Cheating in scientific publishing: the scourge must stop! Liver Int (2008) 0.85
Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy? Hepatology (2003) 0.85
Concurrence of primary biliary cirrhosis and antiphospholipid antibody syndrome. Am J Gastroenterol (2004) 0.84
Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. Clin Infect Dis (2013) 0.84
B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol (2013) 0.84
Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol (2013) 0.83
Characterization of hepatitis B virus genotypes and quantitative hepatitis B surface antigen titres in North American tertiary referral liver centres. Liver Int (2013) 0.83
Pre-acute hepadnaviral infection is associated with activation-induced apoptotic death of lymphocytes in the woodchuck (Marmota monax) model of hepatitis B. Dev Comp Immunol (2010) 0.83
Patient-derived hepatitis C virus and JFH-1 clones differ in their ability to infect human hepatoma cells and lymphocytes. J Gen Virol (2012) 0.83
Differential expression of candidate virus receptors in human T lymphocytes prone or resistant to infection with patient-derived hepatitis C virus. PLoS One (2013) 0.83
Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis. Inflamm Bowel Dis (2007) 0.83
Hepatocytes as cytotoxic effector cells can induce cell death by CD95 ligand-mediated pathway. Hepatology (2006) 0.82
Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis. Am J Physiol Gastrointest Liver Physiol (2008) 0.82
Repeated passage of wild-type woodchuck hepatitis virus in lymphoid cells does not generate cell type-specific variants or alter virus infectivity. J Virol (2008) 0.82
Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy. PLoS One (2013) 0.81
What happens to cirrhotic cardiomyopathy after liver transplantation? Hepatology (2005) 0.81
Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions. Clin Immunol (2009) 0.81
Woodchuck hepatitis virus hepatocyte culture models. Methods Mol Med (2004) 0.80
Altered mesenteric venous capacitance and volume pooling in cirrhotic rats are mediated by nitric oxide. Am J Physiol Gastrointest Liver Physiol (2008) 0.80
Role of cardiac myofilament proteins titin and collagen in the pathogenesis of diastolic dysfunction in cirrhotic rats. J Hepatol (2011) 0.79
Pay now or pay (more) later: tracking the costs of hepatitis C infection. Can J Gastroenterol (2010) 0.79
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. Dig Dis Sci (2014) 0.79
Occult hepatits C virus persistence: identification and characteristics. MLO Med Lab Obs (2006) 0.79
Phenytoin-induced reduction in sirolimus levels. Can J Hosp Pharm (2011) 0.79